Hemorrhagic disease associated with inhibitors of fibrin cross-linkage.
D000368:Aged; D000636:Aminosalicylic Acids / Q000494:pharmacology / Q000627:therapeutic use; D000906:Antibodies; D000937:Antigen-Antibody Reactions; D001665:Binding Sites; D001667:Binding, Competitive; D001777:Blood Coagulation / Q000187:drug effects; D001780:Blood Coagulation Tests; D002118:Calcium; D004789:Enzyme Activation; D005176:Factor XIII / Q000037:antagonists & inhibitors / Q000378:metabolism; D005260:Female; D005337:Fibrin; D006470:Hemorrhage / Q000209:etiology*; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000378:metabolism; D014376:Tuberculosis / Q000188:drug therapy
D000636:Aminosalicylic Acids; D000906:Antibodies; D010455:Peptides; D005337:Fibrin; D005176:Factor XIII; D002118:Calcium; D007538:Isoniazid